Business Context and Reporting Period
Alphatec Holdings, Inc. filed this Form 8-K on October 19, 2012, to report the entry into a Material Definitive Agreement. The Company, a Delaware corporation, entered into an Asset Purchase Agreement with Phygen, LLC to acquire assets related to spinal implant products, including intellectual property, inventories, and certain liabilities.
Key Financial Metrics and Transaction Terms
This filing details a strategic acquisition rather than periodic financial performance. The consideration for the Phygen Assets includes:
- Initial Equity: Issuance of 4,069,087 unregistered shares of common stock.
- Initial Cash: $2 million in cash, subject to adjustment based on the net difference between assumed accounts payable and acquired accounts receivable.
- Escrow Equity: Issuance of 1,170,960 unregistered shares held in escrow for 12 months to secure indemnification obligations.
- Deferred Cash: An additional $4 million payable on April 10, 2013, subject to setoff for indemnification claims.
- Liabilities: Assumption of specified liabilities related to the Phygen Assets.
The filing does not provide current revenue, profit, cash flow, margins, or debt levels for Alphatec Holdings, Inc.
Material Changes and Agreements
The primary material change is the acquisition of Phygen's spinal implant assets and the execution of an Exclusive License Agreement for the "Autolok System" (proprietary set screw locking technology). Key terms include:
- License Terms: Alphatec will pay a royalty on net sales of the Autolok System. An annual minimum royalty payment is required for five years, commencing in the first full calendar quarter following the six-month anniversary of the Closing.
- Lock-Up Restrictions: Phygen is restricted from disposing of the shares received. Restrictions lapse in three tranches on the first, second, and third annual anniversaries of the Closing (1,922,049, 1,658,999, and 1,658,999 shares, respectively).
- Closing Conditions: The transaction is subject to customary conditions, including the absence of legal prohibitions, receipt of consents, and no material adverse effect on the assets.
- Termination Date: Either party may terminate the agreement if the Closing has not occurred by November 15, 2012.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking financial guidance or management commentary on future earnings. However, it outlines specific risks and contingencies:
- Closing Risk: The transaction is not guaranteed and may be terminated if conditions are not met by November 15, 2012.
- Indemnification: The escrow shares and deferred cash payment are contingent upon the absence of indemnification claims.
- Regulatory: The shares are issued in reliance on exemptions from registration under Section 4(2) of the Securities Act and/or Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the final closing date and whether the transaction was consummated before the November 15, 2012 deadline.
- Confirm the exact number of shares issued and the final cash consideration after the accounts payable/receivable adjustment.
- Review the full Asset Purchase Agreement and Autolok License Agreement (expected in the 2012 Form 10-K) for detailed royalty rates and minimum payment amounts.
- Monitor the status of the 1,170,960 escrow shares to determine if any were released to Phygen or used to satisfy claims after the 12-month period.
- Assess the impact of the assumed liabilities on the Company's balance sheet in subsequent filings.